MTOR and Insulin resistance: We hypothesize that CXCR4 antagonists may simultaneously inhibit MAPK, PI3k/AKT, and mTOR signaling pathway, inhibit cholesterol metabolism, and correct insulin resistance, which may exert a stronger inhibitory effect on the BCR signaling pathway.